Lipo-Dox

• For the treatment of AIDS-related Kaposi’s sarcoma in patients with low CD4 (<200 CD4 lymphocytes/mm³) and diseases in mucosa, skin and internal organs.
• For treatment of advanced, recurrent, or metastatic ovarian cancer in women who have failed first-line platinum-based chemotherapy treatment.
• As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
• In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Lonsurf

LONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

UFUR

Gastric cancer, colorectal cancer, breast cancer, combination with cisplatin for metastatic and advanced lung cancer, head & neck cancer, and adjuvant treatment for T2 stage IB lung adenocarcinoma.

TS-1

• For adjuvant chemotherapy treatment of TNM Stage II (exclude T1), IIIA, IIIB gastric cancer in adult patients undergone radical resection. For treatment of unresectable advanced gastric cancer.
• For treatment of locally advanced and metastatic pancreatic cancer patients.
• In combination with Irinotecan for treatment of oxaliplatin treatment failure metastatic colorectal cancer patients.
• For the treatment of previously platinum chemotherapy treated locally advanced and metastatic non-small cell lung cancer.

Pexeda

• Pexeda in combination with cisplatin is indicated for initial treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.
• Pexeda is indicated for maintenance treatment of locally advanced or metastatic non-squamous non-small cell lung cancer patients whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
• Pexeda as a single agent is indicated for second line metastatic non-squamous non-small cell lung cancer treatment.
• Pexeda in combination with cisplatin is indicated for treatment of mesothelioma.

Gemmis

Gemmis is indicated for the treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer and biliary tract cancer. Gemmis is indicated in combination with paclitaxel for anthracycline-treated failure locally-recurred inoperable breast cancer or metastatic breast cancer after failure of prior anthracycline-containing adjuvant or metastatic chemotherapy. Gemmis is indicated in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. Biliary tract cancer.

Oxalip

• In combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:
  1. Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor.
  2. Treatment of metastatic colorectal cancer.
• Oxaliplatin in combination with fluoropyrimidine is indicated for the treatment of locally advanced and recurrent/metastatic gastric cancer.
• In combination with 5 fluorouracil, leucovorin and irinotecan (FOLFIRINOX) as the first-line treatment for metastatic pancreatic cancer.

Irino

Irino is indicated for the treatment of patients with advanced colorectal cancer:
1. In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
2. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
3. In combination with cetuximab, it is used to treat patients with KRAS wild-type metastatic colorectal cancer who have failed cytotoxic therapy with irinotecan and have epithelial growth factor receptor (EGFR) phenotype. (See Pharmacodynamic Properties)
4. In combination with 5 fluorouracil, folinic acid, and bevacizumab as the first-line treatment for patients with metastatic colorectal or rectal cancer.
5. In combination treatment with capecitabine as first-line treatment for patients with metastatic colorectal cancer.
6. In combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFIRINOX) as the first-line treatment for metastatic pancreatic cancer.
7. For patients with unresectable locally advanced and recurrent/metastatic gastric cancer.

Epicin

Mammary carcinoma, malignant lymphoma, soft tissue sarcoma, and gastric, lung and ovarian carcinomas.

Tynen

Breast cancer, non-small cell lung cancer, prostate cancer, head and neck cancer, gastric adenocarcinoma.

Anazo

• Treatment of advanced breast cancer in postmenopausal women. Efficacy has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.
• Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer.
• Adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Folina

To diminish the toxicity and counteract the effect of unintentional over dosage of folic acid antagonist. To treat Folate deficient megaloblastic anemias of infancy, pregnancy, sprue, and nutritional deficiencies.

Folina inj

Antidote indicated in folic acid antagonist (ex. Methotrexate) overdose.

Yondelis

For the treatment of patients with unresectable or metastatic liposarcoma (liposarcoma) or leiomyosarcoma (leiomyosarcoma) who have received a course of treatment containing anthracycline.

Pemazyre

For adults with locally advanced or metastatic cholangiocarcinoma who have received systemic drug therapy and whose tumor has FGFR2 fusions or rearrangements, unresectable condition.

Veiasu

• First-line therapy for locally invasive or metastatic non-small cell lung cancer (NSCLC) patients with EGFR-TK mutations.
• Second-line drug for patients with locally advanced or metastatic lung adenocarcinoma after previous chemotherapy.

Thado

• Newly Diagnosed Multiple Myeloma: Thalidomide should be used in combination with prednisolone and oral melphalan, or with bone marrow transplant. Or be combined with pamidronate in patients after bone marrow transplant.
• Approved for treatment of moderate to severe cutaneous (ENL); not indicated as monotherapy for ENL with moderate to severe neuritis.

Andason

Indicated for the treatment of patients with high risk myelodysplastic syndrome: refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Ivic

• Patients with chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase after failure of interferon-alpha therapy.
• Adult patients with unresectable or metastatic malignant gastrointestinal stromal tumors.
• Newly diagnosed patients with chronic myeloid leukemia (CML).
• Newly diagnosed adult or pediatric patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL), in combination with chemotherapy.
• Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL), used as single agent therapy.
• Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.
• Adult patients with systemic mastocytosis (SM) associated with FIP1L1-PDGFR fusion gene mutation and without the D816V c-Kit gene mutation.
• Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.
• Adult patients with KIT (CD117) positive gastrointestinal stromal tumors (GIST), as post-operative adjuvant therapy after complete gross resection.
• Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.

Asadin

Arsenic trioxide is indicated for the induction of remission and consolidation of acute promyelocytic leukemia characterized by t (15,17) translocation or PML/RAR-alpha gene expression, in patients who are refractory to or have relapsed from retinoid and anthracycline chemotherapy.
The effect of Trioxide on other acute myeloid leukemias has not been studied.

Leavdo

1. Lenalidomide in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation (ASCT).
2. To be used in combination with dexamethasone for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy.

Analide

Essential thrombocythemia.

Bortezomib

1. Used in combination with other cancer treatment drugs for untreated multiple myeloma (MM) patients and who have received at least one treatment modality or patients with advanced multiple myeloid cancer who are not suitable for bone marrow transplantation.
2. For Mantle Cell Lymphoma (MCL) patients.

Painkyl

Painkyl is an opioid analgesic indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking at least: 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.

Megest

Anorexia in patients with AIDS, and significant weight loss due to AIDS or cancer-related cachexia.

Otril

Granisetron extended-release subQ injection is indicated for the prevention of acute and delayed chemotherapy-associated nausea and vomiting in patients receiving regimens with an anthracycline in combination with cyclophosphamide.
It may be used for initial and repeat chemotherapy courses, and must be used in combination with other antiemetics (eg, dexamethasone, neurokinase-1 receptor antagonists).

Zobonic

Bone metastases from solid tumors: Treatment of documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy); prostate cancer should have progressed following treatment with at least one hormonal therapy.
Hypercalcemia of malignancy: Treatment of hypercalcemia (albumin-corrected serum calcium ≥12 mg/dL) of malignancy. Multiple myeloma: Treatment of osteolytic lesions of multiple myeloma.